MannKind Sees Early ReadyFlow Demand as Pediatric Afrezza Launch Gains Momentum

MannKind NASDAQ: MNKD CFO Chris Prentiss outlined the company's commercial and development priorities at the H.C. Wainwright Global Investment Conference, emphasizing execution following three major 2026 catalysts: expanded pediatric approval for Afrezza, the launch of FUROSCIX ReadyFlow, and Phase 1b data for MNKD-201 in idiopathic pulmonary fibrosis, or IPF.

MarketBeat • Sep 17, 2026

Breathing In GLP-1: MannKind Partners With Rose Pharma for Inhaled Weight Management Molecule

MannKind Corporation (NASDAQ:MNKD) shares are trading lower on Wednesday as traders react to the company's entry into a licensing and collaboration deal tied to an inhaled, rapid-acting GLP-1 program.

Benzinga • Sep 9, 2026

MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management

Collaboration combines Rose Pharma investigational rapid-acting GLP-1 receptor agonist with MannKind's Technosphere ® inhalation technology MannKind to receive an equity interest and potential royalties while providing pharmaceutical development and manufacturing support through completion of a Phase 1b clinical study DANBURY, Conn. and WESTLAKE VILLAGE, Calif.

GlobeNewsWire • Sep 9, 2026

MannKind to Present at Upcoming Investor Conferences

DANBURY, Conn. and WESTLAKE VILLAGE, Calif.

GlobeNewsWire • Sep 2, 2026

FDA Accepts United Therapeutics' NDA Filing for Ralinepag in PAH

UTHR's ralinepag NDA receives FDA acceptance, with a 2027 decision ahead as positive phase III data support its PAH potential.

Zacks Investment Research • Aug 28, 2026

MannKind: New Approvals Majorly Increase MannKind's Prospects

Three revenue streams continue to feed modest growth for MannKind. Two new FDA approvals show promise of turbocharging product growth in two of MNKD's established products. MNKD's existing liquidity should be adequate to fund its operations and launches for ~2.3 years.

Seeking Alpha • Aug 13, 2026

MannKind Q2 Earnings Call Highlights

MannKind NASDAQ: MNKD reported second-quarter revenue of $109.4 million, up 43% from the prior-year period, as growth in its commercial products and collaboration revenue helped offset increased spending tied to product launches and development programs.

MarketBeat • Aug 6, 2026

MannKind Corporation (MNKD) Q2 2026 Earnings Call Transcript

MannKind Corporation (MNKD) Q2 2026 Earnings Call Transcript

Seeking Alpha • Aug 6, 2026

MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update

Achieved three major catalysts to drive future growth: Launched the pediatric indication of Afrezza ® following FDA approval FUROSCIX ReadyFlow™ autoinjector approved for treatment of edema in HF and CKD Positive nintedanib DPI Phase 1b data in IPF patients validates continued Phase 2 advancement Encouraging early momentum in Afrezza pediatric launch 1 in 3 of the top 100 pediatric insulin writers have prescribed Q2 2026 total revenues of $109.4M, +43% vs. Q2 2025 Conference call and webcast today at 4:30 p.m.

GlobeNewsWire • Aug 5, 2026

MannKind (MNKD) Reports Q2 Loss, Beats Revenue Estimates

MannKind (MNKD) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to break-even earnings per share a year ago.

Zacks Investment Research • Aug 5, 2026